Swiss pharmaceutical giant Novartis has never been shy about looking outside Europe for research talent. It caused a stir a few years back when it opened a major R&D center in Cambridge, Mass. Now the company will invest $100 million in a new Chinese lab that blends Eastern and Western medicine and targets Asian diseases.
